Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members in a competitive market, the Swiss Biotech Association works to secure favorable framework conditions and facilitate access to talents, novel technologies and financial resources. To strengthen and promote the Swiss biotech industry, the Swiss Biotech Association collaborates with numerous partners and life science clusters globally under the brand Swiss Biotech™.
Our media releases, presentations for the media and useful links
The proposal to the WTO, to weaken the patent protection for COVID-19 vaccines, incorrectly portrays IP as the barrier to rapid access to vaccines. While this initiative does not address the crisis in an effective manner, it does send an extremely dangerous signal to innovators and investors alike. A robust and reliable IP protection is indispensable for science-based innovation. What sounds good at first glance is dangerous as it risks to significantly weaken our ability to foster and finance healthcare innovation.
Capital investments in Swiss biotech companies almost tripled from 2019 to 2020 reaching CHF 3.4B (USD 3.7B) – R&D investments increased by 10% to CHF 2.2B (USD 2.3B) – The number of employees in Swiss R&D biotech companies increased by 8% to 16,300 – High quality patent output helped maintain Switzerland’s top ranking in Global Innovation Index for the tenth consecutive year – From rapid diagnostic test and vaccine manufacturing to drug repurposing, Swiss biotech companies made significant contributions to address the impact of the COVID-19 pandemic
The Swiss Biotech Report “Aglity, leadership and innovation in the time of COVID-19” launched by the Swiss Biotech Association in conjunction with EY and eight other partner organizations provides analysis of funding, M&A activity and collaborations. The report also highlights projects and companies that were part of the Swiss response to the COVID-19 pandemic.
The Swiss Biotech Association will open a representative office at the Basel Chamber of Commerce on April 1, 2021. This demonstrates its commitment to Basel as a life sciences location with its innovative companies. Together with the Basel Chamber of Commerce, they are committed to a strong, competitive life sciences industry in the Basel region and Switzerland.
Download PDF Seit 2018 zeichnet die Swiss Biotech Association hervorragende Leistungen…
Each year, the Swiss Biotech Association awards companies or individuals with the Swiss Biotech Success Stories Awards in recognition of outstanding achievements. Actelion, Debiopharm, Helsinn, Venture Kick, >>Venture>>, Venturelab, and the noble prize-winner Professor Werner Arber receive the awards in 2020.
Each year, the Swiss Biotech Association awards companies or individuals in recognition of outstanding achievements.
The award winners for 2020 are Actelion, Debiopharm, Helsinn, Venture Kick, >>Venture>>, Venturelab, and the noble prize-winner Professor Werner Arber.
Nominated this year for the Swiss Biotech Success Stories Awards in 2021 are Bachem, Basilea, Esbatech, Lonza, and Novimmune.